

15 March 2023

BSF Enterprise PLC
("BSF" or the "Company")

Result of Annual General Meeting

BSF Enterprise (LSE: BSFA), the Main Market listed biotech company and the owner of pioneering UK-based clinical and cellular agriculture company 3D Bio-Tissues, is pleased to announce that at the Company's Annual General Meeting held earlier today, all resolutions proposed were duly passed by shareholders by way of a poll, the results of which were as follows:

Resolution		Poll Results				
		For	Against	Abstain	Discretionary	Total
1	Shares	50,625,257	-	-	-	50,625,257
	%	100%	-	-	-	100%
2	Shares	50,596,092	29,165	-	-	50,625,257
	%	99.94%	0.06%	-	-	100%
3	Shares	50,596,092	29,165	-	-	50,625,257
	%	99.94%	0.06%	-	-	100%
4	Shares	48,471,538	-	2,153,719	-	50,625,257
	%	95.75%	-	4.25%	-	100%
5	Shares	50,596,092	-	29,165	-	50,625,257
	%	99.94%	-	0.06%	-	100%
6	Shares	50,596,092	29,165	-	-	50,625,257
	%	99.94%	0.06%	-	-	100%
7	Shares	50,596,092	-	29,165	-	50,625,257
	%	99.94%	-	0.06%	-	100%

For further enquiries, please visit www.bsfenterprise.com or contact:

BSF Enterprise PLC
Geoff Baker - Non-Executive Director
Che Connon - Executive Director

Via SEC Newgate below

Shard Capital (Broker)
Damon Heath

0203 971 7000

SEC Newgate (Financial Communications)
Bob Huxford
Elisabeth Cowell
George Esmond

020 3757 6882
BSF@secnewgate.co.uk

ISIN of the Ordinary Shares is GB00BHNBDQ51
SEDOL Code is BHNBDQ5.

Notes to Editors

BSF Enterprise PLC (BSF) is focused on unlocking the next generation of biotechnological solutions - using cell-based tissue engineering to help generate cultured meat, lab-grown leather, as well as human corneas, collagen growth and skin substitutes, as part of a radical transformation to deliver sustainable solutions across a variety of sectors.

It owns 100% of 3D Bio-Tissues (3DBT), a tissue engineering with patent-protected IP that is already producing human corneas to help restore vision to millions of people. Building on this success, it aims to produce the UK's first high quality lab-grown meat from its laboratory in Newcastle the next 12 months, transforming the meat-production industry towards an ethical and sustainable practice.

BSF aims to deliver growth to shareholders through the continued commercialisation of 3DBT's IP, which has multiple applications, as well as through M&A. It aims to acquire a suite of technologies that underpins the development of tissue templating for corneas, meat and leather, and license out the IP to manufacturers, wholesalers and distributors to help manufacture the products at scale.